Study #2016-0965
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV181, an Immunotherapy, in Subjects with Advanced Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
ABBV-927, ABBV-181
Description
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors Cancer
Study phase:
Phase I
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-625-0962
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.